tn-201
tn-201: developed by 1 company · 1 clinical trial tracked · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Tenaya Therapeutics, Inc. (TNYA) | Phase 1/Phase 2 |
Clinical Trials (1)
First-in-Human, Open-Label, Safety, Tolerability, Dose-Finding, Pharmacodynamic and Cardiac Transgene Expression Study of TN-201, a Recombinant Adeno-associated Virus Serotype 9 (AAV9) Containing Myosin Binding Protein C Transgene, in Adults With MYBPC3 Mutation-associated Hypertrophic Cardiomyopathy (HCM)
FDA Decisions
Frequently asked questions
Who is developing tn-201?
tn-201 is being developed by Tenaya Therapeutics, Inc..
How many clinical trials involve tn-201?
BioSniper tracks 1 clinical trial involving tn-201.
What is tn-201's latest FDA decision?
The most recent tracked FDA decision for tn-201 is FDA_Meeting for The FDA has removed the clinical hold on the MyPEAK-1 clinical trial of TN-201 gene therapy..
Get deeper analysis on tn-201
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis